First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al.|The Oncologist|2012Cited by 213
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Enrique Aranda, Amelia López-Ladrón et al.|Unknown|2012Cited by 25
Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Molecular Cancer Therapeutics|2017Cited by 22
Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PI3KCA</i> wild type (4WT). GEMCAD 1601 PIER trial.Carlos Fernández-Martos, Carles Pericay, Joan Maurel et al.|Journal of Clinical Oncology|2021Cited by 3
Comparison of three molecular methods to detect mutations in <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i> and <i>PIK3CA</i> in metastatic colorectal cancer (mCRC).Cristina Santos, Ramón Salazar, Rocio García‐Carbonero et al.|Journal of Clinical Oncology|2016Cited by 1